Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

CDH Investments Proposed to Acquire Sirtex Medical for $1.4 Billion

publication date: May 4, 2018

Sirtex Medical Limited announced it had received an unsolicited proposal from CDH Investments, a major Chinese asset management firm, to acquire Sirtex for $1.4B.  CDH made a cash offer for the public Australian oncology treatment device company for $25.15 per share, a 14.2% premium to its closing price. Previously, Varian Medical Systems, Inc., an American radiation equipment provider, made an acquisition offer at $20.96 per share in January. Although CDH’s offer was 20% higher, the Directors of Sirtex said they continue to believe the Varian deal is in the best interest of its shareholders. More details....

Stock Symbol: (ASX: SRX)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital